ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and the Cancer Genome Atlas

Gynecologic Oncology

Volumn 131, Issue 1, 2013, Pages 8-14

  Johnatty, Sharon E ^a   Beesley, Jonathan ^a   Gao, Bo ^b   Chen, Xiaoqing ^a   Lu, Yi ^a   Law, Matthew H ^a   Henderson, Michelle J ^c   Russell, Amanda J ^c   Hedditch, Ellen L ^c   Emmanuel, Catherine ^b   Fereday, Sian ^d   Webb, Penelope M ^a   Goode, Ellen L ^e   Vierkant, Robert A ^e   Fridley, Brooke L ^f   Cunningham, Julie M ^g   Fasching, Peter A ^h,i   Beckmann, Matthias W ^h   Ekici, Arif B ^h   Hogdall, Estrid ^j,k   Kjaer, Susanne K ^j,l   Jensen, Allan ^j   Hogdall, Claus ^j   Brown, Robert ^m   Paul, Jim ⁿ   Lambrechts, Sandrina ^o   Despierre, Evelyn ^o   Vergote, Ignace ^o   Lester, Jenny ^p   Karlan, Beth Y ^p   Heitz, Florian ^q,r   Du Bois, Andreas ^q,r   Harter, Philipp ^q,r   Schwaab, Ira ^s   Bean, Yukie ^t   Pejovic, Tanja ^t   Levine, Douglas A ^u   Goodman, Marc T ^p   Camey, Michael E ^v   Thompson, Pamela J ^v   Lurie, Galina ^v   Shildkraut, Joellen ^w,x   Berchuck, Andrew ^w   Terry, Kathryn L ^y   Cramer, Daniel W ^y   Norris, Murray D ^c   Haber, Michelle ^c   MacGregor, Stuart ^a   DeFazio, Anna ^b   Chenevix Trench, Georgia ^a   more..

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e Mayo Clinic   (United States)

^f UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^g MAYO CLINIC   (United States)

^h UNIVERSITY HOSPITAL ERLANGEN   (Germany)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^k UNIVERSITY OF COPENHAGEN   (Denmark)

^l Rigshospitalet   (Denmark)

^m HAMMERSMITH HOSPITAL   (United Kingdom)

ⁿ UNIVERSITY OF GLASGOW   (United Kingdom)

^o UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^p CEDARS SINAI MEDICAL CENTER   (United States)

^q DR HORST SCHMIDT KLINIKEN   (Germany)

^r KLINIKEN ESSEN MITTE   (Germany)

^s Institut Für Humangenetik Wiesbaden   (Germany)

^t OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^u MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^v UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^w DUKE UNIVERSITY MEDICAL CENTER   (United States)

^x DUKE CANCER INSTITUTE   (United States)

^y BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

ABCB1; Chemotherapy; Genetics; Outcome; Ovarian cancer; Polymorphisms

Indexed keywords

CARBOPLATIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL;

ALLELE; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; GENE; GENE EXPRESSION; GENETIC VARIABILITY; HAPLOTYPE; HAPLOTYPE MAP; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIDRUG RESISTANCE PROTEIN 1 GENE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84885318807     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.07.107     Document Type: Article

References (32)

1. Marchetti C, Pisano C, Facchini G, Bruni GS, Magazzino FP, Losito S, et al. First-line treatment of advanced ovarian cancer: current research and perspectives. Expert Rev Anticancer Ther 2010;10: 47-60.
2. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455: 152-62.
3. Orina JN, Calcagno AM, Wu CP, Varma S, Shih J, Lin M, et al. Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther 2009;8: 2057-66.
4. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 2007;7: 154-79.
5. Sissung TM, Baum CE, Kirkland CT, Gao R, Gardner ER, FiggWD. Pharmacogenetics of membrane transporters: an update on current approaches.Mol Biotechnol 2010;44: 152-67.
6. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 2006;12: 854-9.
7. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 2007;25: 4528-35.
8. Peethambaram P, Fridley BL, Vierkant RA, Larson MC, Kalli KR, Elliott EA, et al. Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome. Int J Mol Epidemiol Genet 2011;2: 185-95.
9. Tian C, Ambrosone CB, Darcy KM, Krivak TC, Armstrong DK, Bookman MA, et al. Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 2012;124: 575-81.
10. Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB, Webb PM, et al. Correction: ABCB1 (MDR1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res 2012;18(1): 319-20.
11. Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB,Webb PM, et al. ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res 2008;14: 5594-601.
12. Gayther SA, Song H, Ramus SJ, Kjaer SK,Whittemore AS, Quaye L, et al. Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res 2007;67: 3027-35.
13. Sankararaman S, Sridhar S, Kimmel G, Halperin E. Estimating local ancestry in admixed populations. Am J Hum Genet 2008;82: 290-303.
14. Huang RS, Johnatty SE, Gamazon ER, Im HK, Ziliak D, Duan S, et al. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res 2011;17: 5490-500.
15. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 2012;44: 955-9.
16. Li Y,Willer C, Ding J, Scheet P, Abecasis G.MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 2010;34: 816-34.
17. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 2013;45: 362-70.
18. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet 2005;37: 1217-23.
19. Cordell HJ, Clayton DG. A unified stepwise regression procedure for evaluating the relative effects of polymorphisms within a gene using case/control or family data: application to HLA in type 1 diabetes. Am J Hum Genet 2002;70: 124-41.
20. Browning SR, Browning BL. Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. Am J Hum Genet 2007;81: 1084-97.
21. Haber M, Smith J, Bordow SB, Flemming C, Cohn SL, LondonWB, et al. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol 2006;24: 1546-53.
22. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3 [RESEARCH0034].
23. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474: 609-15.
24. Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet 2002;359: 1309-10.
25. Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity (Edinb) 2005;95: 221-7.
26. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004;74: 765-9.
27. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 2010;42: 880-4.
28. Song H, Ramus SJ, Kjaer SK, DiCioccio RA, Chenevix-Trench G, Pearce CL, et al. Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. Hum Mol Genet 2009;18: 2297-304.
29. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007;315: 525-8.
30. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res 2007;67: 9609-12.
31. Diaz-Padilla I, Amir E, Marsh S, Liu G, Mackay H. Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: a systematic review. Gynecol Oncol 2012;124: 354-65.
32. Burger RA, Brady MF, BookmanMA,Walker JL, Homesley HD, Fowler J, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. ASCO Meeting Abstracts, 28; 2010. p. LBA1.